EXECUTIVE INTERVIEWS

• Diversity & Inclusion Through The Eyes Of Two Female Pharma Executives

  In the following, we present two first-hand accounts of what it has been like to be a female working in the pharma industry for many years, and what we can all do to overcome the industrywide challenge related to diversity and inclusion.

• Leveling Up By Challenging Assumptions

  An outspoken champion of gender equity and diversity in the workplace, Arcellx CEO Rami Elghandour aims to put the company’s controllable CAR-T therapies on the cover of Time magazine.

• 3 Approaches For Developing Better Drugs To Treat Brain Disorders

  Three organizations pursuing three different strategies for new drug development have one thing in common: optimism about the future of treatments for intractable brain disorders.

• CoCrystal’s Co-CEOs

  Most biopharma industry observers would agree the leadership of a company by two co-equal CEOs is a rare thing. But when it does happen, the unusual arrangement offers useful insights.

• Embracing Challenges And Executing A Successful IPO

  John Jacobs, CEO of Harmony Biosciences, discusses the challenges and lessons learned from when his company transitioned from private to public.

• A New Model For A New Era Of Psychedelic Therapy

  MAPS Public Benefit Corporation hopes to kick off the next golden age of psychedelic therapy with the potential FDA approval of its MDMA candidate for PTSD.

• Platforms To Pipelines: Part 2

  In part 2 of this series, we cover each company’s future plans, as well as their leaders’ observations of the platform-to-pipeline space they are effectively expanding, by joining a gathering crowd of companies now entering it.

• Are Cannabinoids The Next Blockbuster Drugs? A Q&A With Jazz Pharma’s CEO Bruce Cozadd

  A Q&A with Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals, on the $7.2 billion acquisition, integration, and future of cannabis drug pioneer GW Pharmaceuticals.

• Where Patients Meet Policy: The EveryLife Foundation For Rare Diseases

  The year before he founded Ultragenyx, Emil Kakkis created the EveryLife Foundation for Rare Diseases, a nonprofit patient advocacy organization focused on the “equitable development of and access to lifesaving diagnoses, treatments, and cures.” We caught up with Annie Kennedy, chief of policy and advocacy at the EveryLife Foundation, to learn more about the issues and policies the foundation is prioritizing this year.

• Thinking Differently About Rare Disease Therapies

  As Ultragenyx continues building its new gene therapy manufacturing facility, CEO and president Dr. Emil Kakkis talks about his unique outlook on the rare disease space.

• Beyond Profits To Biopharma Innovation

  What if, for certain ambitious but traditionally underfunded areas needing innovation, a startup could achieve its ends without the usual for-profit incentives?

• What’s It Like Being A Termeer Fellow?

  We reached out to four previous Termeer Network Fellows to find out how the program helped them and what they learned. Participants included Sun Altbach, founder and former CEO and president of PIC Therapeutics; Ana Maiques, CEO, Neuroelectrics; Stan Wang, founder & CEO, Thymmune Therapeutuics; and Natalie Yivgi-Ohana, CEO, Minovia Therapeutics.

• Art Of The Startup — Making New Waves

  As Shoreline’s chairman, CEO, and cofounder, Dr. Kleanthis Xanthopoulos draws on his experience of several decades, starting and running companies that aim to overturn prevailing practices in areas of medicine where practice makes imperfect, with treatments that disappoint patients or prove expensive and impractical for many.

• Outsourcing From A To ZZ Biotech

  Kent Pryor, CEO of ZZ Biotech, explains how he’s approached his single-handed “CEO As Outsourcer” role and provides advice to professionals of all positions in any biopharma organization.